Browse Category

NASDAQ:POET News 7 October 2025 - 15 January 2026

POET Technologies Stock Soars on AI Microchip Breakthrough: What NASDAQ:POET Investors Need to Know Now

POET Technologies Stock Soars on AI Microchip Breakthrough: What NASDAQ:POET Investors Need to Know Now

POET Technologies Inc. (NASDAQ: POET) has just pulled off another eye‑catching rally, fueled by a new ultra‑fast AI-focused microchip and a wave of bullish coverage from Wall Street and financial media. As of December 10, 2025, the once‑obscure photonics small cap is suddenly front and center in the AI infrastructure story. This deep dive walks through the latest POET Technologies stock news, analyst forecasts, and key risks so readers can understand why the stock is moving and what could come next. POET Technologies Stock Today: Big Move in a Very Volatile Name POET Technologies stock has been on a wild
POET Technologies (NASDAQ: POET) Stock on December 3, 2025: Cash-Rich AI Optics Play Faces Sharp Volatility After Q3 Earnings

POET Technologies (NASDAQ: POET) Stock on December 3, 2025: Cash-Rich AI Optics Play Faces Sharp Volatility After Q3 Earnings

POET stock price today: where things stand on 3 December 2025 As of the U.S. midday session on December 3, 2025, POET Technologies Inc. (NASDAQ: POET) is trading around $4.68 per share, up roughly 1–2% on the day from a previous close near $4.61. That price values the photonics and AI-connectivity specialist at about $600 million in market capitalization, depending on the data provider. Stock Titan+1 The stock has been on a violent ride. Over the past 52 weeks, POET shares have swung between $3.09 and $9.41, highlighting the name’s high volatility and speculative profile. Public+1 Price history over the
Mystery $75 M Bet Propels Tiny POET Technologies to New Highs Amid AI Frenzy

POET Technologies Stock Soars on $150M Fundraise – AI Photonics Play Heats Up

Market Summary As of the Nov 3 pre-market, POET’s shares hovered around $6.4, up about +1% on the dayreuters.com. The stock’s rally over the last year has been dramatic – Finimize reports roughly a 101% gain in the 12 months through early October 2025, driven by AI-centric optimism and aggressive fundraisingfinimize.com. For context, POET outpaced the S&P 500 (up ~18%) handily, as investors cheered positive news on customers, industry awards and capital raises (the Oct 7 $75M placement was noted as “the largest single financing in its history”investing.com). At its peak in mid-October, POET traded near $9.4stockanalysis.com, but profit-taking following
AI Boom Delivers $75 Million Windfall to POET Technologies – Optical Revolution Ahead?

AI Boom Delivers $75 Million Windfall to POET Technologies – Optical Revolution Ahead?

POET’s $75 Million Bet to Scale AI Connectivity POET Technologies – a Toronto-based designer of photonic chips – has landed a $75 million cash infusion to supercharge its growth in the AI hardware arenatipranks.com. Announced on October 7, the deal was a non-brokered private placement (13.64 million new shares plus warrants) with a single institutional investor, underscoring a strong vote of confidence in POET’s technologyglobenewswire.comglobenewswire.com. The investment “marks the largest single investment in POET’s history” and boosts the company’s balance sheet to over $150 M in cash with no significant debt, according to CEO Dr. Suresh Venkatesanglobenewswire.comglobenewswire.com. “The massive growth of AI infrastructure represents an unprecedented opportunity for which POET is

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop